By Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced the risk for hospitalization for any cause in patients with chronic kidney disease (CKD) with and without type 2 diabetes. The findings suggest that dapagliflozin should be considered in such patients. The study is published in Annals of Internal Medicine.
Dapagliflozin reduces risk for hospitalization in patients with CKD with or without diabetes
A network of molecules and atoms of glass and crystals constitute a single system. 3D illustration
Comments